Antiviral drug-resistant HBV

DOI HANDLE Web Site Web Site PubMed 被引用文献13件 オープンアクセス

書誌事項

タイトル別名
  • Standardization of nomenclature and assays and recommendations for management
公開日
2007-07
権利情報
  • http://doi.wiley.com/10.1002/tdm_license_1.1
DOI
  • 10.1002/hep.21698
公開者
Ovid Technologies (Wolters Kluwer Health)

この論文をさがす

説明

<jats:sec> <jats:title>Abstract</jats:title> <jats:p> <jats:bold>Substantial advances have been made in the treatment of chronic hepatitis B in the past decade. Approved treatments for chronic hepatitis B include 2 formulations of interferon and 4 nucleos(t)ide analogues (NAs). Sustained viral suppression is rarely achieved after withdrawal of a 48-week course of NA therapy, necessitating long, and in many cases, indefinite treatment with increasing risk of development of drug resistance. Antiviral resistance and poor adherence are the most important factors in treatment failure of hepatitis B. Thus, there is a need to standardize nomenclature relating to hepatitis B antiviral resistance, and to define genotypic, phenotypic, and clinical resistance to NA therapy. (HEPATOLOGY 2007;46:254–265.)</jats:bold> </jats:p> </jats:sec>

収録刊行物

  • Hepatology

    Hepatology 46 (1), 254-265, 2007-07

    Ovid Technologies (Wolters Kluwer Health)

被引用文献 (13)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ